New York, NY -- (SBWIRE) -- 04/29/2019 -- The worldwide oligonucleotide synthesis market is growing due to favorable government policies, increasing prevalence of infectious diseases and cancer, advancements in synthesis technology, and ongoing research in synthetic biology. Valued at $1.5 billion in 2017, the domain is predicted to progress with a 10.8% CAGR during the forecast period 2018–2023, ultimately generating $2.8 billion in revenue by 2023. By definition, oligonucleotide synthesis is the artificial creation of oligonucleotides, which are short DNA or RNA fragments.

Request to get the sample pages of the report: https://www.psmarketresearch.com/market-analysis/oligonucleotide-synthesis-market/report-sample

On the basis of offering, reagents and consumables, synthesized oligonucleotides, and equipment are the three market categories. Among these, synthesized oligonucleotides held the largest revenue share (76.3%) in 2017 and is also predicted to grow the fastest during the forecast period, at an 11.1% CAGR. The increase in contract manufacturing of DNAs and RNAs is expected to escalate the demand for synthesized oligonucleotides. Similarly, when segmented by application, the oligonucleotide synthesis market can be categorized into diagnostics, research, and therapeutics.

Among all, the research category led the market in 2017 and is expected to be the fastest growing (11.1% CAGR) category. This pays credence to the finding that of all the end users of synthetic oligonucleotides, including diagnostic laboratories, pharmaceutical and biotechnology companies, academic research institutes, and others, academic research institutes dominated the oligonucleotide synthesis market in 2017 with 40.4% revenue share. This further substantiates the fact that increasing research activities in the field is one of the key growth drivers of the market.

Browse report overview with 131 tables and 61 figures spread through 179 pages and detailed TOC on "Oligonucleotide Synthesis Market" at: https://www.psmarketresearch.com/market-analysis/oligonucleotide-synthesis-market

Over the years, the number of private and public organizations involved in synthetic biology research has grown significantly. Woodrow Wilson International Center for Scholars (Wilson Center), in a 2013 article, reported that the number of companies carrying out research in the field grew from 230 in 2009 to 503 by 2013. Such activities have paved the way for the development of small chemotherapeutic molecules and advanced biopharmaceuticals. Further, developments, including microchip-aided production, are leading to cost-effective and swift manufacturing of oligonucleotides.

In addition, several new products have come in the oligonucleotide synthesis market, such as protecting amino groups, synthesizers with high throughput, and coupling reagents. Similarly, the development of the microarray technology is aiding the production of oligonucleotides for the diagnosis and treatment of diseases. Along with making the nucleotide assembly method efficient and correcting errors in synthesized enzymes, such developments are also helping in the steady progress of the market.

Make enquiry before buying the report: https://www.psmarketresearch.com/send-enquiry?enquiry-url=oligonucleotide-synthesis-market

Now, the oligonucleotide R&D is itself being bolstered by growing government support in the form of funding and other initiatives. The U.S. government invested about $820 million in synthetic biology R&D between 2008 and 2014. Similarly, as per SynbiCITE an England-based organization, the U.K government invested over $400 million during 2009–2016 for establishing three training centers and six research institutes dedicated to synthetic biology. Thus, with favorable government attitude toward providing people with better levels of healthcare, the oligonucleotide synthesis market is predicted to continue on the path to prosperity.

Hence, it is clear that the increase in research and development in the synthetic biology field will further the market advance.